For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is BrightSpring Health Services, Inc. (BTSG) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BrightSpring Health Services, Inc. is one of 986 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zack ...

Icon PLC (ICLR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 23. On the o ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Organon (OGN) . This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat.When looking at the last two reports, this pharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 9.63%, on average, in the last two quarter ...

学科建设与发展是提升诊疗服务能力的关键。为进一步促进乳腺学科建设与发展，中国临床肿瘤学会候任理事长、中国人民解放军总医院肿瘤医学部副 主任江泽飞建议，乳腺内外科的划分与发展应因地制宜。比如，大型肿瘤专科医院资源丰富、团队专业，应细化乳腺内外科，精准应对不同乳腺疾病，满足 患者多元化需求。而基层医疗机构资源有限，应按器官系统整合乳腺内外科资源，组建综合性诊疗团队，方便患者获得全面诊断和治疗。 据了解，为推进科研成果临床转化，助力癌症防控工作，激励广大医务人员修医德、行仁术，用优质的服务增进人民健康福祉，人民健康联合肿瘤防控 领域权威专家学者，于2020年启动了"人民好医生·金山茶花计划"，集中推荐展示了一批在肺癌、肝胆肿瘤、胃癌、食管癌、乳腺癌、妇科肿瘤、泌尿系统 肿瘤、淋巴瘤、鼻咽癌九大肿瘤防治领域做出突出贡献的中青年专家。 闫敏在学术交流现场。 郑州大学附属肿瘤医院乳腺科副主任、主任医师闫敏说："复发转移性乳腺癌患者目前受到的关注不够，全国各医疗机构中乳腺内科专科少，转移性乳 腺癌患者大多就诊乳腺癌外科或全肿瘤内科，对以全身药物治疗为主线，局部治疗为辅助的精准治疗、全程管理和长期生存重视不足，一定程度上影响 ...

改变的关键在于我省推进紧密型县域医共体建设——以市县人民医院为牵头单位，联合乡镇卫生 院、村卫生室等基层医疗机构，形成统一管理单元。"最核心的变化是统一了药品目录，彻底打通了用 药限制。"蔡捷捷介绍，此举显著增加了乡镇卫生院和村卫生室的可用药品种类，让慢病患者能够便捷 地在"家门口"用上所需的药品。 新政策的成效已开始在基层显现。"我们卫生院通过对辖区患者需求的细致摸底，将降压药品种从 过去的几种扩展到现在的十多种，基本覆盖了附近患者的常用药需求。"蔡捷捷院长介绍，这意味着更 多的患者可以免除奔波之苦，真正享受就近的基层医疗服务。 近日，海口市云龙镇长泰村卫生室医生王运铭看着身患高血压病的村民蔡夫丰的检查报告，对照着 一条条数据进行讲解。在了解了他的常用药后，王运铭当场为他开具了降压药。以往，蔡夫丰需要到海 口市第五人民医院取药，如今在家门口的村卫生室就可以拿到这些药。 自深入贯彻中央八项规定精神学习教育开展以来，省卫生健康委坚持学查改、开门教育一体推进， 教育引导党员干部主动担当作为，坚持把脉问诊、对症下药，聚焦百姓看病的"关键事、揪心事"精准发 力，积极推进为民办实事事项，以作风建设新成效提升群众就医获得 ...

Core Insights - The 2025 Xiamen Talent Service Month aims to attract global talent to foster innovation and development in the city [1][2] - The event emphasizes practical matchmaking between talent and enterprises, focusing on technological achievements [2] Talent Initiatives - Xiamen has established global talent workstations to facilitate the flow of international professionals, including the "Heart Sapling Visiting Scholar Program" by Xiamen Cardiovascular Hospital [3] - The program has formed strategic partnerships with leading medical institutions in six countries, attracting 26 young physicians for training [4] Policy and Support - Xiamen introduced the "Eight-point Policy on AI Industry Talent Development" to enhance support for professionals in key areas such as recruitment and cultivation [5] - The "Top 10 AI+Talent Application Scenarios" were also introduced, aligning AI technologies with talent services in various sectors [6] International Engagement - Xiamen has hosted overseas entrepreneurship competitions for seven consecutive years, enhancing its global talent attraction [7] - The inaugural Global Innovation and Entrepreneurship Competition seeks leading talent projects in innovative fields, with over 300 projects registered from nearly 20 countries [8]

Group 1 - Concentra Group (CON) has outperformed its Medical sector peers, gaining approximately 3.3% year-to-date, while the average loss for Medical stocks is 3.3% [4] - The Zacks Rank for Concentra Group is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for Concentra Group's full-year earnings has increased by 1.5% over the past three months, reflecting improved analyst sentiment [4] Group 2 - Concentra Group is part of the Medical Services industry, which consists of 58 stocks and currently ranks 65 in the Zacks Industry Rank, with an average loss of 2.4% year-to-date [6] - Boston Scientific (BSX), another Medical stock, has returned 15.3% year-to-date and has a Zacks Rank of 2 (Buy) [5] - The Medical - Products industry, to which Boston Scientific belongs, has moved up by 6.1% year-to-date and is currently ranked 152 [6]

Core Insights - The article compares GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY) to determine which stock is more attractive to value investors [1] - GDRX has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while HQY has a Zacks Rank of 3 (Hold) [3] Valuation Metrics - GDRX has a forward P/E ratio of 12.80, significantly lower than HQY's forward P/E of 27.57 [5] - The PEG ratio for GDRX is 1.15, while HQY's PEG ratio is 1.32, suggesting GDRX is more favorably valued considering expected earnings growth [5] - GDRX's P/B ratio is 2.64 compared to HQY's P/B of 4.2, further indicating GDRX's relative undervaluation [6] Value Grades - GDRX has earned a Value grade of B, while HQY has a Value grade of D, highlighting GDRX's superior valuation metrics [6] - The combination of solid earnings outlook and favorable valuation figures positions GDRX as the better value option currently [6]

Company Performance - ANIXA BIOSCIENCES INC has gained approximately 35.4% year-to-date, significantly outperforming the Medical group, which has lost about 4.1% on average [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has increased by 7.3% over the past 90 days, indicating improved analyst sentiment and a more positive earnings outlook [3] Industry Context - ANIXA BIOSCIENCES INC is part of the Medical - Biomedical and Genetics industry, which includes 495 companies and currently ranks 75 in the Zacks Industry Rank. This industry has experienced an average loss of 2% year-to-date, showing that ANIX is performing better than its peers [6] - In comparison, CochLear Ltd. Unsponsored ADR, another outperforming stock in the Medical sector, has returned 9.6% since the beginning of the year and is part of the Medical Services industry, which has moved -2.4% year-to-date and ranks 64 [4][7]

Company Overview - Progyny (PGNY) shares increased by 13.2% to $24.27 in the last trading session, with a higher-than-average trading volume, contrasting with a 2.4% loss over the past four weeks [1] - The company is a provider of fertility and family building benefits [2] Financial Performance Expectations - Progyny anticipates its Q2 2025 financial results (revenues, adjusted net income, and adjusted EBITDA) to exceed the guidance provided during the Q1 earnings call [2] - The expected quarterly earnings per share (EPS) is $0.42, reflecting a year-over-year decline of 2.3%, while revenues are projected to be $314.93 million, an increase of 3.6% from the previous year [3] Earnings Estimate Trends - The consensus EPS estimate for Progyny has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Progyny is part of the Zacks Medical Services industry, which includes other companies like Enhabit (EHAB), which experienced a 0.3% decline in the last trading session and has returned -32.1% over the past month [4] - Enhabit has a consensus EPS estimate of $0.1 for its upcoming report, representing a 42.9% increase from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]